RunYoung Management Team
Founder and Chairman
Roger Lu has over 20 years of experience in corporate and financial management, a veteran of cross-border business with Israel and North America and has been responsible for investment in many investments over the years
He joined Sailing in 2018 as General Manager of Sailing Link Capital Management Company.
Prior to that he was with PTL where he provided investment and advisory services to the Israeli market, participated in the completion of more than 20 projects with foreign investment and the establishment of a $1 billion joint venture between Israel’s second largest fund and China Everbright Bank Fund to introduce Israeli projects to the Chinese market. He also led the completion of five projects with Chinese investment in Israeli companies; three in the healthcare sector, one in water treatment and one in the Internet sector.
Chairman and Founding Partner, TCC
Mr. Chen is the founding partner and chairman of TCC. Prior to founding TCC in 2013, Mr. Chen was an executive director at Nomura International (HK) Limited and previously a vice president at Lehman Brothers Asia Limited.
Dr. Benny Zeevi
RunYoung Israel | Managing Partner
Dr. Benny Zeevi is a Managing General Partner at Tel Aviv Venture Partners and DFJ Tamir Fishman Ventures and leads the funds Life Science investments. He is the Founder and Co Director of an Executive Program for Biotechnology and Medical Device Entrepreneurs and Managers and serves on the advisory board of the Faculty of Management at Tel Aviv University.
Dr. Zeevi is the chairman of the boards of Vessl, Kytera and Oggii, and serves on the board of Kaiima, and Sensifree and on the advisory board of V Wave, Bionaut Lab and Data2Life. He holds a M.D. degree (Magna Cum Laude) from the Sackler School of Medicine, Tel Aviv University and has authored over 60 peer-reviewed scientific articles, in addition to various chapters in textbooks and invited reviews and editorials in pediatric cardiology journals.
Medical and Scientific Consultants
Prof. Aaron Ciechanover
Nobel Prize Winner
PhD, Israeli Biologist and Chemist.
The first Israeli to win a Nobel Prize in the sciences, Dr. Ciechanover is a member of the Israeli Academy of Humanities and Natural Sciences, a foreign member of the US National Academy of Sciences, a foreign member of the Chinese Academy of Sciences, a Distinguished University Professor at The Chinese University of Hong Kong (Shenzhen), President of the Chehanovo Institute of Precision and Regenerative Medicine and Director of the Institute of Chemical and Biomedical Sciences at Nanjing University.
Along with Dr. Avram Hershko and in collaboration with Dr. Irwin A. Rose from the Fox Chase Cancer Center in Philadelphia, Aaron discovered that covalent attachment of ubiquitin to a target protein signals it for degradation. Along the years it has become clear that ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders. Consequently, the system has become an important platform for drug development.
Prof. Gad Keren
Professor Gad Keren is a professor of Cardiology at the Sackler school of Medicine and from 2002 until October 2018, he was the Head of the department of Cardiology at the Tel Aviv Sourasky Medical Center (TASMC). He is currently the director of Cardiology at the Assuta chain of Medical centers and leads the basic Cardiovascular research laboratory at TASMC. He spent years doing research at the Albert Einstein College of Medicine in New York and at the NIH in Washington DC.
Professor Keren held the Chaim Sheba Extraordinary Chair of Cardiology at the Tel Aviv University where he served as Vice dean of Curriculum of the Sackler school of Medicine. He was the president of the Israel Heart Society and served on multiple national and international Academic committees over the years, He is also the deputy editor of the IMAJ and Harefua Medical journals.
Professor Keren’s main lines of research have evolved from hemodynamics and cardiac imaging, heart failure and mechanisms of disease progression and he has authored more than 400 scientific publications and has numerous patents.
Prof. Eli Keshet
Prof. Eli Keshet, an academician of the Israeli Academy of Sciences, received his Ph.D. in biochemistry in 1975 and then conducted postdoctoral research on retroviral integration and the reverse locus sub-subject under the direction of Nobel Laureate Howard Tymin. From 1980 to 1981, Eli was a professor of molecular biology in the Department of Developmental Biology and Cancer Research at the Weizmann Institute, where he joined the faculty in 1982. He is a visiting scientist at the National Cancer Institute, the Curie Institute in Paris and Harvard Medical School. He is also an advisor to many major pharmaceutical companies including Roche, Schering-Plough and Novartis and recipient of numerous awards including the E.M.E.T. Prize (awarded by the Prime Minister of Israel), the Rothschild Prize, the TEVA Prize, the Bennett Prize and others.
Prof. Moshe Flugelman
Prof. Moshe Flugelman specializes in interventional cardiology and vascular biology. He is the Director of the Department of Cardiovascular Medicine at the Lady Davis Carmel Medical Center, Haifa, Israel.
He was a visiting Scientist at the National Heart, Lung & Blood Institute of the National Institutes of Health (NIH) in Bethesda, Maryland and was a fellow in experimental angioplasty at Washington Hospital Center. While at the NIH, Prof. Flugelman worked with leading experts in vascular gene therapy.
Prof. Flugelman earned his Medical degree at the Technion – Israel Institute of Technology and completed his cardiology training at the Hadassah Hebrew University Medical Center in Jerusalem.
RunYoung Think Tank Industry Consultants
Yi Zhang, PhD
Dr. Yi Zhang has been involved in the medical device industry for more than twenty years and has a deep knowledge of Chinese medical device innovation. He is the founder and chairman of Peijia Medical. Dr. Yi Zhang received his B.S. degree in Chemical Engineering from Zhejiang University in July 1988, specializing in production process automation and his M.S. degree in Chemical Engineering from Zhejiang University in March 1991 specializing in medical device and apparatus automation. He received his PhD degree in Engineering Science from the University of Toledo in March 1997. Prior to joining the Group, Dr. Zhang worked at Medtronic Plc. from 1996 to 1998. From 1998 to 2002, Dr. Zhang was a senior engineer in the research and development department of Guidant Corporation. From February 2002 to June 2006, Dr. Zhang served as the Chief Executive Officer of Microport.
Mr. Ming Zhong
Mr. Zhong founded Kanji Medical Holdings in 2004 and is its executive director, Chairman of the Board and CEO. He also serves as an executive director of Kangyin Investment since and the vice president at Surgery Medical Equipment Branch of China Association of Medical Equipment. Previously he found Tonglu Kangpu, an MISIA distributor. Mr. Zhong received his bachelor’s degree in business administration from China University of Geosciences.
Mr. Zhong was awarded the Outstanding Hangzhou Entrepreneur by World Hangzhou Entrepreneur Convention held by The People’s Government of Hangzhou City in 2018 and was awarded Outstanding T-Merchants by Conference of
T-Merchants held by The People’s Government of Tonglu County in 2016.